428863-50-7
428863-50-7
Chemical Structure
Certolizumab pegol
Synonym(s): Certolizumab; CDP870
- CAS No.: 428863-50-7
- Formula:N/A
- Molecular Weight:(91 kDa)
SMILES: [Certolizumab pegol]
Biological Activity: Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Certolizumab pegol | 99.00% | Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97. [Content Brief]
- [2]. Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32. [Content Brief]
